Commencing a job within project no, POIR.01.01.01-00-0123/16 entitled“Development of Selective Endometriosis Therapy Based on Mesoprogestins” we invite to submit a tender for SAFETY PHARMACOLOGY CARDIOVASCULAR SYSTEM STUDY IN DOG FOR EC313 COMPOUND
Below please find the documents
Read more
Łódź, August 27th, 2018
EXPLANATIONS OF THE CONTENT OF RFP NO. ZO-08-2018
TO ALL INTERESTED PARTIES
By using the point 10 Chapter VI, the Employer informs that in the public procurement procedure for the development of the formulation of an experimental medicinal product for use in a clinical trial, conducted in the mode of the request for proposals under the provisions of the Act of 23 April 1964 – Civil Code (ie the Official Journal 2017, item 459) inquiries from Contractors. The content of the queries together with the explanations are included below.
IMPORTANT NOTICE: The ordering party extends the time of submitting bids until 24/09/2018 by 12:00
IMPORTANT NOTICE: The ordering party also informs that in the content of the offer the obvious clerical errors and inconsistencies between the Polish and English versions have been corrected.
IMPORTANT NOTICE: In connection with the change introduced in terms of time stability studies the RFP has been changed. One may download it below
Read more
Commencing a research task within project no, POIR.01.01.01-00-0123/16 entitled“Development of Selective Endometriosis Therapy Based on Mesoprogestins” we invite to submit a tender for FORMULATION DEVELOPMENT OF AN INVESTIGATIVE MEDICINAL PRODUCT INTENDED FOR CLINICAL RESEARCH USE.
Read moreIn relation to implementation of the project No. POIR.01.01.01-00-0123/16 entitled “The development of selective treatment of endometriosis based on mesoprogestins“, conducted within Action 1.1. „R&D projects of enterprises”, Sub-action 1.1.1. „Industrial research and development works carried out by enterprises” in frame of Priority I of POIR 2014 – 2020″ as well in connection with the obligation to apply the competitive principle (principle of fair competition) Evestra Onkologia Sp. z o. o. invites to submit offers for successive supply of:
REQUEST FOR PROPOSALS FOR METABOLIC STABILITY AND METABOLITE IDENTIFICATION STUDIES IN MICROSOMES AND S9 FRACTION OF DOG, MONKEY, RABBIT AND RATFOR EC313 COMPOUND
Below please find the RFP and attachment no. 5
Read more
By following point 10 of Chapter VI, the ordering party informs that within the request for proposals for
FORMULATION DEVELOPMENT OF AN INVESTIGATIVE MEDICINAL PRODUCT INTENDED FOR CLINICAL RESEARCH USE
conducted in the mode of inquiry based on the provisions of the Act of April 23, 1964 – the Civil Code (Journal of Laws 2014, item 212, as amended), questions were recieved. Please find the questions and answers are below:
ZO-12-2017_Answers to the questions_1
Read moreIn relation to implementation of the project No. POIR.01.01.01-00-0123/16 entitled “The development of selective treatment of endometriosis based on mesoprogestins“, conducted within Action 1.1. „R&D projects of enterprises”, Sub-action 1.1.1. „Industrial research and development works carried out by enterprises” in frame of Priority I of POIR 2014 – 2020″ as well in connection with the obligation to apply the competitive principle (principle of fair competition) Evestra Onkologia Sp. z o. o. invites to submit offers for:
commencement of reproductive toxicology studies
Below please find the RFP file and Request for proposals ZO-11-2017
Read more
In relation to implementation of the project No. POIR.01.01.01-00-0123/16 entitled “The development of selective treatment of endometriosis based on mesoprogestins“, conducted within Action 1.1. „R&D projects of enterprises”, Sub-action 1.1.1. „Industrial research and development works carried out by enterprises” in frame of Priority I of POIR 2014 – 2020″ as well in connection with the obligation to apply the competitive principle (principle of fair competition) Evestra Onkologia Sp. z o. o. invites to submit offers for:
FORMULATION DEVELOPMENT OF AN INVESTIGATIVE MEDICINAL PRODUCT INTENDED FOR CLINICAL RESEARCH USE
The rfp files are uploaded below:
Read more
Due to server failure the Ordering Party extends the deadline for submission of tenders until September 1, 2017, until 18:00.
Read moreBy following point 10 of Chapter VI, the ordering party informs that within the request for proposals for
pre-clinical tests (physiochemical, ADME-tox, genotoxicity, safety pharmacology and toxicological tests) necessary to commence 1st phase clinical trials for EC313,
conducted in the mode of inquiry based on the provisions of the Act of April 23, 1964 – the Civil Code (Journal of Laws 2014, item 212, as amended), questions were recieved. Please find the questions and answers are below:
ZO-07-2017_Answers-to-the-questions_5
Read moreBy following point 10 of Chapter VI, the ordering party informs that within the request for proposals for
pre-clinical tests (physiochemical, ADME-tox, genotoxicity, safety pharmacology and toxicological tests) necessary to commence 1st phase clinical trials for EC313,
conducted in the mode of inquiry based on the provisions of the Act of April 23, 1964 – the Civil Code (Journal of Laws 2014, item 212, as amended), questions were recieved. Please find the questions and answers are below:
ZO-07-2017_answers-to-the-questions_4
Read more
